FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Vet Intern Med / Effect of phenylbutazone administration on the enteroinsular...
Journal of veterinary internal medicine2024; 39(1); e17256; doi: 10.1111/jvim.17256

Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation.

Abstract: Phenylbutazone is prescribed for laminitis-associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID). Objective: Investigate the effect of phenylbutazone administration on the enteroinsular axis in horses. Methods: Sixteen horses, including 7 with ID. Methods: Randomized cross-over study design, with horses assigned to treatment with phenylbutazone (4.4 mg/kg IV q24h) or placebo (5 mL 0.9% saline). On Day 9 of treatment, an OGT was conducted, followed by a 10-day washout period, administration of the alternative treatment, and repetition of the OGT. Glucose-dependent insulinotropic polypeptide (GIP), and active glucagon-like peptide 1 and 2 (aGLP-1 and GLP-2) concentrations were determined by ELISA. The effects of ID status and treatment on peptide concentrations were assessed using t tests and analyses of variance. Results: Horses with ID had significantly higher maximum GIP concentrations (Cmax) than controls (median, 279.1; interquartile range [IQR], 117.5-319.4 pg/mL vs median, 90.12; IQR, 74.62-116.5 pg/mL; P = .01), but no significant effect of ID was detected on aGLP-1 and GLP-2 concentrations. In horses with ID, phenylbutazone treatment significantly decreased GIP Cmax compared with placebo (168.1 ± 59.26 pg/mL vs 242.8 ± 121.8 pg/mL; P = .04), but no significant effect of phenylbutazone was detected on aGLP-1 and GLP-2 concentrations. Conclusions: Glucose-dependent insulinotropic polypeptide, aGLP-1 and GLP-2 do not mediate the decrease in glucose and insulin concentrations observed after phenylbutazone administration. Only GIP was repeatedly associated with ID status, calling into question the role of the enteroinsular axis in ID.
© 2024 The Author(s). Journal of Veterinary Internal Medicine published by Wiley Periodicals LLC on behalf of American College of Veterinary Internal Medicine.
Get Full Text
Publication Date: 2024-11-22 PubMed ID: 39578373PubMed Central: PMC11627515DOI: 10.1111/jvim.17256Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This is a study about the impact of medication Phenylbutazone on horses suffering from insulin dysregulation. It suggests that only Glucose-dependent insulinotropic polypeptide (GIP) seems to be associated with insulin dysregulation (ID) status, while other peptides are not involved.

Methodology

  • This study included 16 horses, of which 7 had insulin dysregulation (ID). The experiment was conducted following a randomized cross-over study design.
  • The horses selected were subjected to treatment with phenylbutazone or a placebo. The dosage of phenylbutazone prescribed was 4.4 mg/kg IV q24h while the placebo horses were given 5 mL 0.9% saline.
  • After nine days of treatment, the horses underwent an oral glucose test (OGT), which was followed by a 10-day washout period.
  • Post this, the alternative treatment was administered and the OGT was repeated.
  • The study measured the concentrations of Glucose-dependent insulinotropic polypeptide (GIP), and active glucagon-like peptide 1 and 2 (aGLP-1 and GLP-2) using ELISA tests.
  • The effects of ID status and treatment on peptide concentrations were analyzed using t tests and analyses of variance.

Results

  • The study found that horses with ID had significantly higher maximum GIP concentrations than healthy horses.
  • However, there was no significant change in the concentrations of aGLP-1 and GLP-2 in relation with the ID status.
  • Phenylbutazone therapy showed a meaningful decrease in GIP in horses with ID as compared to the placebo treatment.
  • No significant effect of phenylbutazone was detected on aGLP-1 and GLP-2 concentrations.

Conclusion

  • The research concluded that a decrease in glucose and insulin concentrations after the administration of phenylbutazone was not mediated by GIP, aGLP-1 or GLP-2.
  • It was only GIP that was consistently linked with ID status, hinting towards the debatable role of the enteroinsular axis in insulin dysregulation.

Cite This Article

APA
Kemp KL, Skinner JE, Bertin FR. (2024). Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation. J Vet Intern Med, 39(1), e17256. https://doi.org/10.1111/jvim.17256

Publication

Journal of veterinary internal medicine
ISSN: 1939-1676
NlmUniqueID: 8708660
Country: United States
Language: English
Volume: 39
Issue: 1
Pages: e17256

Researcher Affiliations

Kemp, Kate L
  • School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia.
Skinner, Jazmine E
  • School of Agriculture and Environmental Science, University of Southern Queensland, 487 - 35 West St, Darling Heights, Queensland, 4350, Australia.
Bertin, François-René
  • School of Veterinary Science, The University of Queensland, 5391 Warrego Hwy, Gatton, Queensland, 4343, Australia.
  • College of Veterinary Medicine, Department of Veterinary Clinical Sciences, Purdue University, 625 Harrison St, West-Lafayette, Indiana, 47909, USA.

MeSH Terms

  • Animals
  • Horses
  • Phenylbutazone / therapeutic use
  • Phenylbutazone / administration & dosage
  • Phenylbutazone / pharmacology
  • Horse Diseases / drug therapy
  • Cross-Over Studies
  • Insulin / blood
  • Male
  • Female
  • Glucose Tolerance Test / veterinary
  • Gastric Inhibitory Polypeptide / blood
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Glucagon-Like Peptide 1
  • Blood Glucose / drug effects

Grant Funding

  • D19-EQ-302 / Morris Animal Foundation
  • The University of Queensland Graduate School Research Training Program (RTP) Scholarship and Destination Australia Scholarship: Awarded to Kate L. Kemp

Conflict of Interest Statement

Authors declare no conflict of interest.

References

This article includes 33 references
  1. Frank N, Tadros EM. Insulin dysregulation.. Equine Vet J 2014;46:103‐112.
    pubmed: 24033478
  2. de Laat MA, McGree J, Sillence M. Equine hyperinsulinemia: investigation of the enteroinsular axis during insulin dysregulation.. Am J Physiol Endocrinol Metab 2016;310:E61‐E72.
    pubmed: 26530154
  3. de Laat MA, Sillence MN. The repeatability of an oral glucose test in ponies.. Equine Vet J 2017;49:238‐243.
    pubmed: 27038020
  4. Mudaliar SMD, Henry RRMD. Effects of incretin hormones on β‐cell mass and function, body weight, and hepatic and myocardial function.. Am J Med 2010;123:S19‐S27.
    pubmed: 20206728
  5. Fitzgerald DM, Walsh DM, Sillence MN, Pollitt CC, Laat MA. Insulin and incretin responses to grazing in insulin‐dysregulated and healthy ponies.. J Vet Intern Med 2019;33:225‐232.
    pmc: PMC6335545pubmed: 30506731
  6. de Laat MA, Fitzgerald DM, Sillence MN, Spence RJ. Glucagon‐like peptide‐2: A potential role in equine insulin dysregulation.. Equine Vet J 2018;50:842‐847.
    pubmed: 29502360
  7. de Laat MA, McGowan CM, Sillence MN, Pollitt CC. Hyperinsulinemic laminitis.. Vet Clin North Am Equine Pract 2010;26:257‐264.
    pubmed: 20699173
  8. Stokes SM, Bertin FR, Stefanovski D. Lamellar energy metabolism and perfusion in the euglycaemic hyperinsulinaemic clamp model of equine laminitis.. Equine Vet J 2020;52:577‐584.
    pubmed: 31845378
  9. de Laat MA, Reiche DB, Sillence MN, McGree JM. Incidence and risk factors for recurrence of endocrinopathic laminitis in horses.. J Vet Intern Med 2019;33:1473‐1482.
    pmc: PMC6524073pubmed: 30972832
  10. Soma LR, Uboh CE, Maylin GM. The use of phenylbutazone in the horse.. J Vet Pharmacol Ther 2012;35:1‐12.
    pubmed: 21668837
  11. Beretta C, Garavaglia G, Cavalli M. COX‐1 and COX‐2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: an in vitro analysis.. Pharmacol Res 2005;52:302‐306.
    pubmed: 15939622
  12. Knych HK, Arthur RM, McKemie DS. Phenylbutazone blood and urine concentrations, pharmacokinetics, and effects on biomarkers of inflammation in horses following intravenous and oral administration of clinical doses.. Drug Test Anal 2019;11:792‐803.
    pubmed: 30499176
  13. Kimple ME, Keller MP, Rabaglia MR. Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose‐ and hormone‐stimulated insulin secretion.. Diabetes 2013;62:1904‐1912.
    pmc: PMC3661627pubmed: 23349487
  14. Nauck M, HÄRter S, Ebert R, Creutzfeldt W. Effects of four orally administered analogues of prostaglandin E1 and E2 on glucose tolerance and on the secretion of pancreatic and gastrointestinal hormones in man.. Eur J Clin Invest 1989;19:298‐305.
    pubmed: 2509214
  15. Kemp KL, Skinner JE, Bertin F‐R. Effect of phenylbutazone on insulin secretion in horses with insulin dysregulation.. J Vet Intern Med 2024;38:1177‐1184.
    pmc: PMC10937495pubmed: 38363029
  16. Henneke DR, Potter GD, Kreider JL, Yeates BF. Relationship between condition score, physical measurements and body fat percentage in mares.. Equine Vet J 1983;15:371‐372.
    pubmed: 6641685
  17. Carter RA, Treiber KH, Geor RJ, Douglass L, Harris PA. Prediction of incipient pasture‐associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies.. Equine Vet J 2009;41:171‐178.
    pubmed: 19418747
  18. Pratt‐Phillips SE, Geor RJ, McCutcheon LJ. Comparison among the euglycemic‐hyperinsulinemic clamp, insulin‐modified frequently sampled intravenous glucose tolerance test, and oral glucose tolerance test for assessment of insulin sensitivity in healthy Standardbreds.. Am J Vet Res 2015;76:84‐91.
    pubmed: 25535665
  19. Burns TA, Geor RJ, Mudge MC, McCutcheon LJ, Hinchcliff KW, Belknap JK. Proinflammatory cytokine and chemokine gene expression profiles in subcutaneous and visceral adipose tissue depots of insulin‐resistant and insulin‐sensitive light breed horses.. J Vet Intern Med 2010;24:932‐939.
    pubmed: 20649750
  20. Dunbar LK, Mielnicki KA, Dembek KA, Toribio RE, Burns TA. Evaluation of four diagnostic tests for insulin dysregulation in adult light‐breed horses.. J Vet Intern Med 2016;30:885‐891.
    pmc: PMC4913564pubmed: 27013065
  21. Chameroy KA, Frank N, Elliott SB, Boston RC. Comparison of plasma active glucagon‐like peptide 1 concentrations in normal horses and those with Equine Metabolic Syndrome and in horses placed on a high‐grain diet.. J Equine Vet Sci 2016;40:16‐25.
  22. Leschke DH, Muir GS, Hodgson JK, Coyle M, Horn R, Bertin FR. Immunoreactive insulin stability in horses at risk of insulin dysregulation.. J Vet Intern Med 2019;33:2746‐2751.
    pmc: PMC6872612pubmed: 31617618
  23. Hornung RW, Reed LD. Estimation of average concentration in the presence of nondetectable values.. Appl Occup Environ Hyg 1990;5:46‐51.
  24. Kheder MH, Sillence MN, Bryant LM, de Laat MA. The equine glucose‐dependent insulinotropic polypeptide receptor: a potential therapeutic target for insulin dysregulation 1.. J Anim Sci 2017;95:2509‐2516.
    pubmed: 28727072
  25. Kheder MH, Bailey SR, Dudley KJ, Sillence MN, de Laat MA. Equine glucagon‐like peptide‐1 receptor physiology.. PeerJ 2018;2018:e4316.
    pmc: PMC5793710pubmed: 29404215
  26. Bamford NJ, Baskerville CL, Harris PA, Bailey SR. Postprandial glucose, insulin, and glucagon‐like peptide‐1 responses of different equine breeds adapted to meals containing micronized maize.. J Anim Sci 2015;93:3377‐3383.
    pubmed: 26440006
  27. Frank N, Walsh DM. Repeatability of oral sugar test results, glucagon‐like peptide‐1 measurements, and serum high‐molecular‐weight adiponectin concentrations in horses.. J Vet Intern Med 2017;31:1178‐1187.
    pmc: PMC5508339pubmed: 28543933
  28. Bamford NJ, Stewart AJ, El‐Hage CM, Bertin FR, Bailey SR. Investigation of breed differences in plasma adrenocorticotropic hormone concentrations among healthy horses and ponies.. Vet J 2023;296‐297:105995.
    pubmed: 37207985
  29. Sibthorpe PEM, Fitzgerald DM, Sillence MN, de Laat MA. Associations between feeding and glucagon‐like peptide‐2 in healthy ponies.. Equine Vet J 2023;56:309‐317.
    pubmed: 37705248
  30. de Laat MA, Sillence MN. Diagnosis of equine endocrinopathies: the value of measuring blood glucose during an oral glucose test.. Vet J 2023;300‐302:106034.
    pubmed: 37778651
  31. Bamford NJ, Potter SJ, Baskerville CL, Harris PA, Bailey SR. Influence of dietary restriction and low‐intensity exercise on weight loss and insulin sensitivity in obese equids.. J Vet Intern Med 2019;33:280‐286.
    pmc: PMC6335535pubmed: 30520164
  32. Consortium TU. UniProt: the universal protein knowledgebase in 2023.. Nucleic Acids Res 2023;51:D523‐D531.
    pmc: PMC9825514pubmed: 36408920
  33. Pinho AR, Fortuna A, Falcão A. Comparison of ELISA and HPLC‐MS methods for the determination of exenatide in biological and biotechnology‐based formulation matrices.. J Pharm Anal 2019;9:143‐155.
    pmc: PMC6598173pubmed: 31297291
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.